Other

Verla-pharm Arzneimittelfabrik Apotheker H.j.v. Ehrlich Gmbh & Co. Kg

Verla-pharm Arzneimittel-fabrik Apotheker H. J. V. Ehrlich

Bayer Aktiengesellschaft

Verla-pharm Arzneimittelfabrik Apotheker H.j. V. Ehrlich Gmbh & Co.

Verlapharm Von Ehrlich A.g.

Joachim Helbig

Klaus F Kopp

Hans G Classen

Franz Fischer

Peter Fischer

Claus-Peter Reisinger

Sven Michael Hansen

Hubert Schmidbaur

Konrad Triebeneck

The invention relates to a process for the removal of deposits formed in a reaction apparatus by the precipitation of solids from a liquid reaction mixture, which process is characterized in that particles of a material that is inert under the reaction conditions are introduced into the reaction apparatus, which particles, by suitable mechanical circulation of the reaction mixture, are so moved through the reactor that, during the reaction, by striking the walls or other built-in elements, they abrasively remove precipitates adhered thereto.

Method for removing deposits from chemical reactors

An orally administered pharmaceutical agent that is particularly suited for iron and magnesium substitutive therapy is disclosed. This drug consists of a combination of one or more pharmaceutically and physiologically compatible iron compounds, one or more pharmaceutically and physiologically compatible magnesium compounds, and, if the magnesium compounds do not contain any chlorine atoms dissociable in aqueous media and saturating the available magnesium valences, the drug further consists of one or more pharmaceutically and physiologically compatible compounds providing chlorine ions in aqueous media. The iron compounds, magnesium compounds and chlorine ion supplying compounds may be mixed with the conventional pharmaceutical solvents and/or thinners and/or auxiliary matter. Unexpectedly, this drug makes it possible to simultaneously administer magnesium or calcium compounds with iron compounds, without thereby causing reduced iron resorption.

Orally administered pharmaceutical agent for iron and magnesium

The invention relates to an agent for the prophylaxis of cardiac infarcti and for the prevention or reinfarctions, and is characterized by the fact that said agent comprises a combination of magnesium amino dicarboxylic acid halides, basic magnesium amino dicarboxylic acid salts, and magnesium halides, singly or in combination, on the one hand, and acetylsalicylic acid, on the other hand, as well as conventional pharmaceutical carriers, diluents, and/or adjuvants, as required.

Method for the prophylaxis of cardiac infarctions and the prevention of

The invention concerns a novel process for the production of a complex cound comprising an amino-dicarboxylic acid ion component, a bivalent metal ion component, and a halogen ion component, which comprises the step of reacting together in an aqueous medium an amino-dicarboxylic acid compound, a bivalent metal compound, and a halogen compound, the proportions of said compounds being chosen so that one of each of said ion components is comprised in the aqueous medium, the bivalent metal compound being selected from the oxide, hydroxide, carbonate or a halide of the bivalent metal, and the halogen compound being said halide of the bivalent metal or a hydrogen halide. Certain of the complexes are novel and find use in a variety of medical and veterinary fields.

Process for the production of amino-dicarboxylic acid-bivalent

The invention concerns a novel pharmaceutical preparation and methods of treatment associated therewith. More particularly, the invention is concerned with pharmaceutical preparations adapted to form or release resorbable bicarbonate ions only in the intestine of the subject. The oral dosage forms of the invention may comprise further active agents, and trace elements. The dosage forms are for example useful in treating patients suffering from abnormal distribution or retention of body fluids or retention products, i.e. products which should be or which should desirably be cleared by kidney function.

Pharmaceutical preparations for and treatment procedures involving

The invention concerns a method of treating a subject suffering from abnormal distribution and retention of body fluids such as may be the result of altered renal function, which comprises the step of administering to a subject in need of such treatment, a therapeutically effective amount of a pharmaceutically acceptable alkaline acting substance capable of increasing patient plasma bicarbonate level to a value in excess of that prior to treatment. Oral preparations, in particular an alkaline substance capable of releasing bicarbonate ions, for therapy of a large variety of ailments and diseases, are disclosed.

Therapy of conditions which may be associated with altered renal

The invention concerns sedative preparations suitable for calming of animals and a method of sedating a warm-blooded animal other than human, comprising the step of administering to such a warm-blooded animal which it is desired to sedate, a magnesium aminodicarboxylic acid chloride, or a magnesium salt of an aminodicarboxylic acid in combination with magnesium chloride, at a dosage sufficient to sedate said warm-blooded animal.

Sedative preparation for animals and method

The invention disclosed concerns a magnesium monospartate hydrochloride and more particularly its use in the prophylaxis of heart necroses.

Use of magnesium monospartate hydrochloride complex

The invention concerns magnesium-containing pharmaceutical compositions comprising at least one of magnesium diglutamate and magnesium diaspartate and one or more alkali or alkaline earth metal halogenide such as magnesium chloride, bromide or iodide, sodium or potassium chloride, bromide or iodide and calcium chloride, bromide or iodide. Combinations comprising lithium chloride or bromide and strontium chloride or bromide are also disclosed. The combinations are intended for use in raising magnesium levels in plasma and bone structures in warm blooded mammals.

Growing community of inventors

Tutzing, Germany

Joachim Helbig